FIELD: medicine.
SUBSTANCE: invention is related to compounds of formula I , or its pharmaceutically acceptable salt of this, in which: R1 means C1-6-aliphatic group, besides, R1 may be substituted with substituents in number of up to 2 groups, independently selected from -OR or -C1-3 halogenalkyl; each R independently means hydrogen or C1-4-aliphatic group; R2 means R, fluorine or chlorine; m means 0, 1 or 2; and R3 means hydrogen, C1-3-aliphatic group, fluorine or chlorine, to composition for inhibition of activity of protein kinase ERK1 or ERK2, on the basis of these compounds, to method for inhibition of activity of protein kinase ERK1 or ERK2, and also to use of compounds of formula I or composition on their basis, for treatment or reduction of disease severity.
EFFECT: new compounds are produced and described, which may be used as inhibitors of protein kinases.
11 cl, 7 ex, 3 tbl
Title | Year | Author | Number |
---|---|---|---|
SPIROCYCLIC COMPOUNDS | 2016 |
|
RU2745069C2 |
4,5-DIHYDRO-[1,2,4]TRIAZOLO[4,3-F]PTERIDINES AS PROTEIN KINASE Plk1 INHIBITORS FOR TREATING PROLIFERATIVE DISEASES | 2007 |
|
RU2441006C2 |
PYRROLOPYRAZINES SUITABLE AS AURORA A KINASE INHIBITORS | 2005 |
|
RU2394825C2 |
ERK2 HETEROCYCLIC INHIBITORS AND THEIR USING | 2002 |
|
RU2300377C2 |
COMPOUNDS USED AS ATR KINASE INHIBITORS | 2013 |
|
RU2689996C2 |
HETEROARYL COMPOUNDS AND USING THEM | 2009 |
|
RU2536584C2 |
HETEROARYL COMPOUNDS AND THEIR APPLICATION | 2010 |
|
RU2636584C2 |
HETEROARYL COMPOUNDS AS IRAK TYPE II INHIBITORS AND THEIR USE | 2019 |
|
RU2810338C2 |
PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2001 |
|
RU2340611C2 |
BENZIMIDAZOLES USED AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2415853C2 |
Authors
Dates
2009-12-20—Published
2005-05-13—Filed